Zoll Medical Corporation
10/14/2024 | Press release | Distributed by Public on 10/14/2024 07:05
ZOLL Announces Closing of Acquisition of Select Vyaire Ventilator Product Lines
CONTACT:
Matt HoganZOLL Medical Corporation+1 (978) 805-6561[email protected]ZOLL Announces Closing of Acquisition of Select Vyaire Ventilator Product Lines
October 14, 2024 - CHELMSFORD, Mass. - ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it successfully completed its previously announced acquisition of certain assets of Vyaire Medical's ventilator business.
With the acquisition complete, ZOLL will immediately make available to customers the bellavista®, fabian®*, LTV®, and 3100 HFOV product lines alongside ZOLL's other respiratory care offerings. For these acquired product lines, all ventilators and associated consumables, service parts, accessories, and service program offerings will continue to be sold where currently available. Existing Vyaire contact channels will remain available for use during a transition period. Customers can also contact ZOLL at [email protected].
"ZOLL's acquisition of select Vyaire ventilator product lines is an exciting opportunity for our customers and our company," said Jon Rennert, CEO of ZOLL. "We now have the ability to serve even more patients and customers, furthering our mission of improving patient outcomes and helping save lives."
*Not available for sale in the U.S.
About ZOLL
ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary and respiratory conditions. For more information, visit www.zoll.com.
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit www.asahi-kasei.com.
Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.
Copyright © 2024 ZOLL Medical Corporation. All rights reserved. ZOLL, bellavista, fabian, and LTV are registered trademarks of ZOLL Medical Corporation and/or its subsidiaries in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.
###